No profile data available.
Eupraxia Pharmaceuticals Inc. (EPRX) is a healthcare company in the bone and joint treatment drugs industry, based in Victoria, Canada, with about 49 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$38.58 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $492.91 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Eupraxia Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$492.91 million as of October 9, 2026.
Listed companies of a similar size in the same industry (bone and joint treatment drugs) include Entera Bio Ltd. (ENTX), Mereo BioPharma Group plc (MREO), Dogwood Therapeutics, Inc. (DWTX), Enlivex Therapeutics Ltd. (ENLV).